---

---

tags : Cancer    crawled time : 12:30   

save search

---

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
Published: 2024-04-23 (Crawled : 12:30) - globenewswire.com
ARTL | News | $1.3004 1.87% 15K |

Health Technology

| 0.77% | O: 0.77% H: 2.29% C: 0.0%
cancer publication therapy

---

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Published: 2024-04-08 (Crawled : 12:30) - globenewswire.com
NVCT | $6.63 -6.62% -7.09% 39K |

| -15.02% | O: 0.45% H: 0.51% C: 0.26%
nxp900 lung cancer cell

---

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA | News M | $91.07 2.78% 2.7% 1.1M |

Health Services

| -1.75% | O: 2.12% H: 4.35% C: 2.25%
bladder positive cancer trial

---

Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements at AACR 2024 with the Potential to Transform Cancer Diagnostics and Treatments
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -1.93% | O: -1.77% H: 0.0% C: -1.81%
SNY | News | $47.69 1.15% 1.13% 1.7M |

Health Technology

| -3.16% | O: -3.44% H: 0.0% C: 0.0%
biomarker cancer diagnostics potential

---

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K |

Health Technology

| -17.86% | O: -4.16% H: 1.07% C: -2.28%
association cancer pancreatic tumor research preclinical for meeting

---

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
EFTR | $1.92 7.87% 7.29% 150K |

| -87.36% | O: -76.55% H: 13.89% C: -17.78%
lung cancer cell topline trial therapeutics results

---

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Published: 2024-04-03 (Crawled : 12:30) - prnewswire.com
GNPX | $2.32 7.26% 6.77% 30K |

Health Technology

| -18.66% | O: 1.76% H: 13.15% C: 7.61%
reqorsa lung cancer treat cell trial therapy study

---

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research
Published: 2024-04-02 (Crawled : 12:30) - biospace.com/
LH M | $207.97 2.41% 0.0% 930K |

Health Services

| -5.69% | O: -0.1% H: 0.01% C: -1.94%
precision association cancer research meeting

---

Maverix Medical Closes Acquisition of Cirrus Bio as Foundation for Diagnostics Platform in Lung Cancer
Published: 2024-03-29 (Crawled : 12:30) - prnewswire.com
HOLX | $77.19 1.27% 1.26% 1.6M |

Health Technology

| Email alert Add to watchlist
lung cancer acquisition medical diagnostics foundation platform

---

Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
Published: 2024-03-28 (Crawled : 12:30) - biospace.com/
EXAS | $63.55 1.83% 1.79% 1.7M |

Health Technology

| -5.01% | O: 0.96% H: 0.0% C: 0.0%
oncoguard test cancer sciences

---

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
Published: 2024-03-27 (Crawled : 12:30) - globenewswire.com
LIXT | $3.3 -1.49% -1.52% 40K |

Health Technology

| 42.79% | O: 77.38% H: 10.0% C: -12.0%
lb-100 cancer publication

---

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
Published: 2024-03-27 (Crawled : 12:30) - globenewswire.com
ALLR | $1.41 -0.7% -0.71% 800K |

n/a

| 359.55% | O: 0.32% H: 2.87% C: 2.87%
approval cancer therapeutics advanced

---

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
Published: 2024-03-21 (Crawled : 12:30) - globenewswire.com
LIXT | $3.3 -1.49% -1.52% 40K |

Health Technology

| 39.39% | O: -2.16% H: 2.21% C: 2.18%
lb-100 update cancer immunotherapy

---

IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
Published: 2024-03-19 (Crawled : 12:30) - prnewswire.com
ICCM | $1.22 0.82% 66K |

Manufacturing

| 0.83% | O: 2.07% H: 0.0% C: 0.0%
free company breast one positive cancer women topline medical alternative results

---

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
Published: 2024-03-19 (Crawled : 12:30) - globenewswire.com
ATOS | $1.485 4.58% 4.38% 1.1M |

Health Technology

| 15.5% | O: 1.55% H: 19.85% C: 18.32%
breast update cancer treatment program therapeutics

---

Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
Published: 2024-03-18 (Crawled : 12:30) - biospace.com/
NTRA | News M | $91.07 2.78% 2.7% 1.1M |

Health Services

| 1.7% | O: 0.19% H: 1.46% C: 0.48%
cancer trial

---

FDA Adcomm Backs Geron’s Anemia Drug for Blood Cancer
Published: 2024-03-15 (Crawled : 12:30) - biospace.com/
GERN | $3.495 -6.3% -6.72% 10M |

Health Technology

| 100.0% | O: 71.43% H: 16.33% C: 12.0%
fda drug anemia cancer blood

---

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
Published: 2024-03-12 (Crawled : 12:30) - globenewswire.com
ATOS | $1.485 4.58% 4.38% 1.1M |

Health Technology

| 24.17% | O: 2.5% H: 8.13% C: 6.5%
breast cancer specialist therapeutics

---

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| Email alert Add to watchlist
cld-101 california institute hope cancer city funding

---

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CGEN | $2.03 3.57% 3.45% 450K |

Health Technology

| -22.11% | O: -1.36% H: 4.48% C: -4.14%
symposium cancer immunotherapy

---

Gainers vs Losers

78%

22%

Top 10 Gainers

MTTR | News 4 | $4.6 164.37% 62.17% 28M |

AGBA | $2.94 135.2% 57.48% 66M |

Finance

EDBL | News | $6.46 71.81% 41.8% 2M |

MTC | $2.25 44.23% 30.67% 6M |

Technology Services

OPRT | News | $3.175 41.11% 29.13% 12M |

Finance

SHIM | $3.05 35.56% 26.23% 1.1M |

HKIT | $1.345 31.86% 24.16% 390K |

Technology Services

ABVC | $1.36 30.77% 23.53% 7.4M |

Wholesale Trade

OST | $0.512 28.0% 21.88% 290K |

POET | $1.59 27.2% 21.38% 4.2M |

Manufacturing

---

Your saved searches

---